
E3 Ligand-Linker Conjugate 1
CAS No. 2098488-36-7
E3 Ligand-Linker Conjugate 1( Azido-Thalidomide | AzidoThalidomide | Azido Thalidomide )
Catalog No. M13317 CAS No. 2098488-36-7
E3 Ligand-Linker Conjugate 1 is an E3 ligand- Linker Conjugate for PROTAC.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 46 | Get Quote |
![]() ![]() |
5MG | 75 | Get Quote |
![]() ![]() |
10MG | 110 | Get Quote |
![]() ![]() |
25MG | 177 | Get Quote |
![]() ![]() |
50MG | 268 | Get Quote |
![]() ![]() |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameE3 Ligand-Linker Conjugate 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionE3 Ligand-Linker Conjugate 1 is an E3 ligand- Linker Conjugate for PROTAC.
-
DescriptionE3 Ligand-Linker Conjugate 1 is an E3 ligand- Linker Conjugate for PROTAC.
-
In Vitro——
-
In Vivo——
-
SynonymsAzido-Thalidomide | AzidoThalidomide | Azido Thalidomide
-
PathwayPROTACs
-
TargetE3 Ligase Ligand
-
RecptorE3 Ligase Ligand
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number2098488-36-7
-
Formula Weight428.405
-
Molecular FormulaC19H20N6O6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 41 mg/mL (95.70 mM)
-
SMILESO=C(NCCCCN=[N+]=[N-])COC1=CC=CC(C(N2C(CC3)C(NC3=O)=O)=O)=C1C2=O
-
Chemical NameN-(4-azidobutyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Schiedel M, et al. J Med Chem. 2017 Apr 17. doi: 10.1021/acs.jmedchem.6b01872.
molnova catalog



related products
-
VHL-2
A VHL ligand for PROTAC.
-
VH-032
VH-032 (VHL ligand 1) is a VHL ligand for PROTAC and potent, small molecule inhibitor of the VHL/HIF-1α interaction with Kd of 185 nM.
-
PROTAC-VHL-ligand
PROTAC-VHL-ligand is a von Hippel–Lindau (VHL) ligand used for the proteolysis targeting chimeras (PROTACs) method, induces target protein degradation.